Sale to Lovell Minnick Partners
Sarepta is a commercial-stage biopharmaceutical company focused on helping patients through the discovery and development of unique RNA-targeted therapeutics, gene therapy and other genetic medicine approaches for the treatment of rare neuromuscular diseases. By applying its' proprietary RNA-targeted platform technologies, Sarepta is able to develop candidate therapies for a broad range of rare diseases and disorders